NRG
GILD icon

Nemes Rush Group’s Gilead Sciences GILD Stock Holding History

Nemes Rush Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39M Sell
26,864
-76
-0.3% -$10K 0.28% 65
2026
Q1 		$3.75M Buy
26,940
+168
+0.6% +$23.5K 0.36% 62
2025
Q4 		$3.29M Buy
26,772
+264
+1% +$32.1K 0.31% 62
2025
Q3 		$2.94M Buy
26,508
+4,158
+19% +$473K 0.29% 61
2025
Q2 		$2.48M Buy
22,350
+21,612
+2,928% +$2.3M 0.27% 66
2025
Q1 		$82.7K Hold
738
– – 0.01% 271
2024
Q4 		$68.2K Sell
738
-5,858
-89% -$527K 0.01% 273
2024
Q3 		$483K Buy
6,596
+5,715
+649% +$436K 0.07% 117
2024
Q2 		$60.4K Sell
881
-5,740
-87% -$383K 0.01% 247
2024
Q1 		$485K Sell
6,621
-23,220
-78% -$1.79M 0.07% 119
2023
Q4 		$2.42M Sell
29,841
-230
-0.8% -$17.9K 0.39% 55
2023
Q3 		$2.25M Sell
30,071
-290
-1% -$22.3K 0.41% 56
2023
Q2 		$2.34M Buy
+30,361
New +$2.42M 0.41% 56

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nemes Rush Group's GILD Position: Q2 2026 in Review

Nemes Rush Group reduced its Gilead Sciences (GILD) stake by 0.28% in Q2 2026, selling an estimated $10K and leaving 26,864 shares worth $3.39M. The position accounts for 0.28% of the portfolio, ranked #65.

Nemes Rush Group first reported a position in GILD in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.75M in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Nemes Rush Group held 26,864 shares of Gilead Sciences worth $3.39M as of Q2 2026.
  • Nemes Rush Group sold 76 Gilead Sciences shares in Q2 2026, an estimated $10K.
  • Gilead Sciences made up 0.28% of Nemes Rush Group's portfolio in Q2 2026, its #65 holding.
  • Nemes Rush Group first reported a position in Gilead Sciences in Q2 2023 and has held it in 13 quarters since.
  • Nemes Rush Group's Gilead Sciences position peaked at $3.75M in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.